In a follow‐up study, the authors have reported the results of hybrid approach efficacy, pharmacokinetics and safety in mice and primates injected with AAV8.MYO7A dual hybrid vector for the treatment of retinitis pigmentosa associated with USH1B. The gene discussed is MYO7A; the disease is retinitis pigmentosa.